Search This Blog

Monday, August 4, 2025

Acting NASA chief Sean Duffy to announce plans for building nuclear reactor on the moon

 It’s a power move.


The Trump administration aims to accelerate the construction of a nuclear reactor on the moon, Transportation Secretary and acting NASA Administrator Sean Duffy wrote in a memo distributed internally on Monday.

The space agency has previously explored the possibility of installing an electricity-generating nuclear reactor on the lunar surface capable of powering a sustained human presence, but Duffy intends to fast-track the project and more than double the reactor’s power output, according to documents obtained by The Post.

Transportation Secretary and acting NASA Administrator Sean Duffy announced plans to build a nuclear reactor on the moon.AP Photo/George Walker IV

“To properly advance this critical technology to be able to support a future lunar economy, high power energy generation on Mars, and to strengthen our national security in space, it is imperative the agency move quickly,” Duffy wrote in the memo.

“It is about winning the second space race,” a NASA senior official told Politico, which first reported on Duffy’s plans.

Duffy’s directive will instruct NASA to seek out proposals for a 100-kilowatt nuclear reactor that would be ready for launch by 2030. 

In 2022, NASA’s “Fission Surface Power Project” awarded design contracts for a 40-kilowatt nuclear reactor, which the agency said is capable of powering 33 households. 

If another country, such as China or Russia, were to build a reactor on the moon first, it could “declare a keep-out zone which would significantly inhibit the United States,” Duffy’s order noted. 

The directive calls for NASA to appoint a leader for the reactor project and to get private industry input within 60 days. 

The planned reactor would be complete by 2030.IndustryAndTravel – stock.adobe.com

NASA will look for private spaceflight companies able to get the reactor to the moon by 2030, when China intends to launch a manned moon mission. 

President Trump named Duffy, 53, the acting head of NASA last month after he withdrew the nomination of billionaire Jared Isaacman, an ally of ex-DOGE chief Elon Musk. 

The surprise move came in response to a “review” of Isaacman’s history, Trump said at the time.

Isaacman has donated tens of thousands of dollars to Democratic candidates and causes as recently as October 2024, when he gave more than $41,000 to the Democratic Senatorial Campaign Committee, Federal Election Commission records show.

A NASA senior official reportedly said the plan is about “winning the second space race.”Alberto Ghizzi Panizza/ SWNS.com

Duffy outlined NASA’s ambitious objectives — to circle the moon, land and eventually build a base on the surface — last month in an interview with Fox News host Sean Hannity.

“We’re going to go back to the moon during Donald Trump’s presidency,” he told Hannity. 

“Next year … start of the year, we are going to go back to the moon. We’re not going to land. We’re going to go around the moon. And then about a year later, we’re going to land back on the moon,” Duffy explained. “And then after that, we’re going to set up a base camp.

“We’re going to stay on the moon, and what we learn on the moon is what’s going to take us to Mars.”

A spokesperson for NASA did not respond to The Post’s request for comment.

https://nypost.com/2025/08/04/us-news/acting-nasa-chief-sean-duffy-to-announce-plans-for-building-nuclear-reactor-on-the-moon/

Ardelyx Q2 2025 beats earnings expectations, ups guidance

 Ardelyx Inc (ARDX) reported its Q2 2025 earnings on August 4, revealing a notable earnings surprise. The company posted a net loss of $0.08 per share, beating analysts’ expectations of a $0.13 loss. Revenue reached $97.7 million, surpassing the forecast of $82.51 million, representing an 18.41% surprise. Following the announcement, Ardelyx’s stock price saw a modest increase, closing at $4.33, up by 1.39% during after-hours trading. 

Key Takeaways

  • Ardelyx reported a narrower-than-expected loss of $0.08 per share.
  • Revenue grew by 33% year-over-year, driven by strong sales of IBSRELA and EXPOSA.
  • The company raised its full-year guidance for IBSRELA, indicating confidence in continued growth.
  • Ardelyx is making strategic moves to improve prescription fulfillment and expand market presence.

Company Performance

Ardelyx demonstrated robust performance in Q2 2025, with total revenue climbing 33% compared to the same period last year, continuing its impressive revenue growth trajectory of 127% over the last twelve months. This growth was largely attributed to the success of its key products, IBSRELA and EXPOSA. The company’s strategic focus on expanding its sales force and enhancing market access is paying off, as evidenced by increased prescription rates and refill activity. The company maintains a strong liquidity position with a current ratio of 4.12, indicating robust ability to meet short-term obligations.

Financial Highlights

  • Revenue: $97.7 million, a 33% increase year-over-year
  • Net loss: $19.1 million, improved from $41 million in the previous quarter
  • Cash and equivalents: $238.5 million
  • IBSRELA net sales: $65 million, an 84% increase year-over-year
  • EXPOSA net sales: $25 million, a 7% increase quarter-over-quarter

Earnings vs. Forecast

Ardelyx’s earnings per share of -$0.08 exceeded the forecasted -$0.13, marking a 38.46% surprise. This positive deviation from expectations highlights the company’s effective cost management and revenue growth strategies. The revenue surprise of 18.41% further underscores the strong demand for Ardelyx’s products.

Market Reaction

Following the earnings release, Ardelyx’s stock price increased by 1.39% in after-hours trading, closing at $4.33. The stock remains below its 52-week high of $7.18 but is significantly above its 52-week low of $3.21. While the stock has experienced a -21.56% return over the past six months, the modest stock movement reflects investor confidence in the company’s performance and future prospects. The company maintains a beta of 0.6, indicating lower volatility compared to the broader market.

Outlook & Guidance

Ardelyx has raised its full-year revenue guidance for IBSRELA to $250-$260 million, signaling optimism about sustained demand. The company is also focused on achieving cash flow breakeven and expects its selling, general, and administrative expenses to rise to approximately $90 million quarterly as it invests in commercial activities.

Executive Commentary

CEO Mike Robb emphasized the company’s commitment to patient-centric innovation, stating, "We are united by a deep commitment to patients backed by best-in-class science." Chief Commercial Officer Eric Foster expressed confidence in the company’s market opportunities, noting, "We feel very confident in the opportunity that’s in front of us."

https://www.investing.com/news/transcripts/earnings-call-transcript-ardelyx-q2-2025-beats-earnings-expectations-93CH-4168994

Semler Scientific Q2 2025 earnings beat

 Semler Scientific Inc. (SMLR) reported a remarkable earnings beat for Q2 2025, with earnings per share (EPS) of $5.04, significantly surpassing the forecast of -$0.22. The company’s revenue also exceeded expectations, coming in at $8.22 million against a forecast of $8.1 million. Following the earnings release, the stock rose 2.67% during the regular trading session and gained an additional 1.39% in the aftermarket, closing at $34.94. 

Key Takeaways

  • Semler Scientific’s EPS exceeded forecasts by a significant margin.
  • Revenue surpassed expectations, reflecting strong financial performance.
  • The stock saw an increase in both regular and aftermarket trading.
  • The launch of the CardioVanta subsidiary signals innovation in healthcare.
  • Strengthened Bitcoin strategy could attract cryptocurrency-focused investors.

Company Performance

Semler Scientific’s performance in Q2 2025 was marked by a substantial earnings beat, with EPS reaching $5.04. The company’s total revenues were $8.2 million, although this represented a decrease from the previous year. Despite an operating loss of $1.2 million, the company reported a net income of $66.9 million, buoyed by an unrealized Bitcoin gain of $83.8 million. The company continues to innovate, launching the CardioVanta subsidiary to focus on heart failure and cardiac arrhythmia monitoring.

Financial Highlights

  • Revenue: $8.2 million (decreased YoY)
  • EPS: $5.04 (exceeded forecast of -$0.22)
  • Net Income: $66.9 million
  • Operating Loss: $1.2 million
  • Cash and Equivalents: $13.6 million
  • Unrealized Bitcoin Gain: $83.8 million

Earnings vs. Forecast

Semler Scientific’s actual EPS of $5.04 was a significant surprise, surpassing the forecast of -$0.22 by 2390.91%. Revenue also exceeded expectations, coming in at $8.22 million compared to the $8.1 million forecast. This performance marks a notable deviation from expectations and is likely to boost investor confidence.

Market Reaction

Following the earnings announcement, Semler Scientific’s stock rose by 2.67% during regular trading and an additional 1.39% in the aftermarket. The stock’s movement reflects positive investor sentiment, driven by the earnings beat and the company’s strategic initiatives. With a beta of 1.4, SMLR shows higher volatility than the broader market. The stock remains within its 52-week range, with a high of $81.555 and a low of $21.77.

Outlook & Guidance

Looking forward, Semler Scientific plans to continue its disciplined Bitcoin acquisition strategy, aiming for 10,000 Bitcoin by the end of 2025. The company is also exploring capital raising options and potential outside investment for its CardioVanta subsidiary, indicating a focus on growth and innovation.

Executive Commentary

Joe Burnett, Director of Bitcoin Strategy, emphasized the company’s commitment to Bitcoin, stating, "The only thing better than Bitcoin is more Bitcoin." This highlights the company’s strategic focus on cryptocurrency as a key component of its financial strategy.

https://www.investing.com/news/transcripts/earnings-call-transcript-semler-scientific-q2-2025-earnings-beat-forecasts-93CH-4168966

Bolsonaro Placed Under House Arrest By US-Sanctioned Brazilian Supreme Court Head

 Late Monday there's been more escalation in the Trump-Brazil standoff over the legal fate of former Brazilian President Jair Bolsonaro. The country's top justices have ordered him to be put under house arrest.

The Supreme Court, which is still in the process of ruling on the Bolsonaro case - as he's accused of an alleged coup attempt against his leftist rival President Luiz Inácio Lula da Silva - has now said he has defied a court order banning Bolsonaro from social media.

Jair Bolsonaro and justice Alexandre de Moraes. source: Secom/TSE

They say he's attacking the nation's institutions while still on trial, and after he's already wearing a ankle monitoring brace.

Brazil has faced US sanctions (targeting among others Bolsonaro's main rival and man driving what Trump has called a "witch hunt" - Supreme Court Justice Alexandre de Moraes) as well as the highest tariff rates in the world.

Moraes himself issued the house arrest order, despite now being specifically targeted by the Trump administration.

"Moraes said Bolsonaro had violated precautionary measures imposed by the court restricting the former president’s social media usage and political messaging," according to Al Jazeera.

Moraes has said that Bolsonaro, who was president of the country between 2019 and 2022, has spread messages with "a clear content of encouragement and instigation to attacks against the Supreme Court and a blatant support for foreign intervention in the Brazilian Judiciary."

Trump's recent heightened intervention has added fuel to the fire, and the standoff has intensified, with the Lula government so far having refused to bend the knee.

Bolsonaro's family members have also been very vocal, often acting as 'messenger' - for example hailing Trump's punitive actions targeting the Supreme Court and Lula officials.

Sunday saw tens of thousands of Bolsonaro supporters in the streets, in the major cities of Sao Paulo and Rio de Janeiro. They, with Trump, want a full pardon for Bolsonaro and his officials which have been persecuted with him.

https://www.zerohedge.com/geopolitical/us-sanctioned-brazilian-supreme-court-head-places-bolsonaro-under-house-arrest

Trump is Serious About U.S. Critical Minerals Dominance, NioCorp Says

NioCorp Developments Ltd. ("NioCorp" or the "Company") (NASDAQ:NB) is praising a reported plan by the Trump Administration to establish price supports for production in the U.S. of rare earth oxides and potentially other minerals deemed critical by the U.S. government.

"President Trump is on track to establish both U.S. energy and critical minerals dominance, and what he is proposing shows that he is willing to go toe-to-toe with foreign nations that manipulate markets and pricing in a manner that discourages U.S. production," said NioCorp Chairman and CEO Mark A. Smith. "Establishing price support levels under the Defense Production Act for critical minerals such as rare earth sends a very powerful signal to industry and financial markets. It says that President Trump is willing to use every available tool under U.S. law to re-assert US leadership in critical minerals mining, processing, and value-added manufacturing."

"The U.S. has enormous critical minerals resources, and President Trump is clearly determined to unlock those resources in order to protect our national defense and economic security," Mr. Smith added. "He also knows that we can produce these minerals while protecting our environment. I am proud that our Elk Creek Critical Minerals Project is one such project, which is why we are fully permitted to move to a construction start immediately after our financing is complete."

NioCorp's Elk Creek Project plans to deliver six critical minerals to the U.S.: Niobium, Scandium, Titanium and three magnetic rare earth oxides: Neodymium-Praseodymium, Dysprosium, and Terbium.

https://finviz.com/news/127069/trump-is-serious-about-us-critical-minerals-dominance-niocorp-says